Current Treatment Options in Oncology

, Volume 10, Issue 1, pp 1–15

Treatment of Hematologic Neoplasms with New Immunomodulatory Drugs (IMiDs)

Chronic Leukemia

DOI: 10.1007/s11864-008-0077-x

Cite this article as:
Wiernik, P.H. Curr. Treat. Options in Oncol. (2009) 10: 1. doi:10.1007/s11864-008-0077-x

Abstract

Thalidomide and its derivatives represent a new class of antineoplastic drugs (IMiDs), which has been especially effective in certain hematologic malignancies. These agents have anti-inflammatory, antiangiogenic, and immunomodulatory properties, and target tumor cells by direct cytotoxicity and indirectly by interfering with several components of the bone marrow microenvironment [1]. Thalidomide analogs that retain antitumor activity equal to or greater than the parent compound, but with less toxicity, have been developed [2]. This paper summarizes what is known about the mechanisms of action of these agents, and recent clinical results. The data suggest that thalidomide analogs will play a major role in the management of certain hematologic neoplasms in the near future.

Copyright information

© Current Medicine Group LLC 2008

Authors and Affiliations

  1. 1.Comprehensive Cancer CenterMontefiore Medical Center—North DivisionBronxUSA
  2. 2.Departments of Medicine and Radiation MedicineNew York Medical CollegeNew YorkUSA